New Joint Initiative For More Efficient, Adaptable Clinical Practice Guidelines 19/02/2019 David Branigan Wellcome Trust, the Bill & Melinda Gates Foundation and the African Academy of Sciences have joined together in a new initiative to make clinical practice guidelines more efficient and adaptable for clinical trials that require less stringent approaches, such as those that take place during infectious disease outbreaks. Additionally, by applying a more flexible approach towards the application of these guidelines, the initiative also hopes to make them “future proof,” or able to better incorporate new technologies. Continue reading -> Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Board Debates Medicines Access; WHO Asserts Mandate On IP, Trade Issues 30/01/2019 Catherine Saez Shortages, faulty supply chains, unbearable prices, weak health systems - the issue of access to medicines is multifaceted and gave way to a long list of interventions yesterday at the World Health Organization. Challenged on its mandate to address intellectual property and trade issues, WHO Director General Tedros Adhanom Gheyebresus (Dr Tedros) confirmed that WHO’s mandate includes work with partners on those issues. Discussions also included fair pricing and transparency, for which Italy called for a resolution at the next World Health Assembly. Continue reading -> Breaking News: WHO Board Completes Work On Access To Medicines Roadmap 29/01/2019 Catherine Saez After 65 interventions by member states and non-governmental organisations, at press time the World Health Organization Executive Board concluded work on a document containing a draft roadmap to increase access to medicines and vaccines. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Italy Floats Proposal For New Deal On Drug Pricing At World Health Assembly 18/02/2019 Elaine Ruth Fletcher Italian Health Minister Giulia Grillo has proposed that sweeping reforms be considered by the World Health Organization and its member states to increase global transparency of drug prices -- which may be unaffordable to most people in the developing world and increasingly costly for patients and health systems in high-income countries. Continue reading -> ‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Board Debates Medicines Access; WHO Asserts Mandate On IP, Trade Issues 30/01/2019 Catherine Saez Shortages, faulty supply chains, unbearable prices, weak health systems - the issue of access to medicines is multifaceted and gave way to a long list of interventions yesterday at the World Health Organization. Challenged on its mandate to address intellectual property and trade issues, WHO Director General Tedros Adhanom Gheyebresus (Dr Tedros) confirmed that WHO’s mandate includes work with partners on those issues. Discussions also included fair pricing and transparency, for which Italy called for a resolution at the next World Health Assembly. Continue reading -> Breaking News: WHO Board Completes Work On Access To Medicines Roadmap 29/01/2019 Catherine Saez After 65 interventions by member states and non-governmental organisations, at press time the World Health Organization Executive Board concluded work on a document containing a draft roadmap to increase access to medicines and vaccines. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
‘Netflix’ Pricing Model Eases Australians’ Access To Expensive Hepatitis C Drugs 14/02/2019 Elaine Ruth Fletcher An innovative five-year agreement between the Australian government and pharmaceutical companies, involving a lump sum payment of about US$ 766 million for an unlimited five-year supply of the most advanced Hepatitis C (HCV) drugs, has reduced the per-patient costs of these cutting-edge treatments by roughly 85%, according to a study today in the New England Journal of Medicine. Continue reading -> New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Board Debates Medicines Access; WHO Asserts Mandate On IP, Trade Issues 30/01/2019 Catherine Saez Shortages, faulty supply chains, unbearable prices, weak health systems - the issue of access to medicines is multifaceted and gave way to a long list of interventions yesterday at the World Health Organization. Challenged on its mandate to address intellectual property and trade issues, WHO Director General Tedros Adhanom Gheyebresus (Dr Tedros) confirmed that WHO’s mandate includes work with partners on those issues. Discussions also included fair pricing and transparency, for which Italy called for a resolution at the next World Health Assembly. Continue reading -> Breaking News: WHO Board Completes Work On Access To Medicines Roadmap 29/01/2019 Catherine Saez After 65 interventions by member states and non-governmental organisations, at press time the World Health Organization Executive Board concluded work on a document containing a draft roadmap to increase access to medicines and vaccines. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New US Corporate Accountability Platform Takes Aim At High Drug Prices 13/02/2019 David Branigan A new corporate accountability platform launched in the United States aims to hold companies accountable by inviting shareholders and consumers to vote on how companies should address issues of the public interest. As its inaugural issue, the platform takes aim at high drug prices. Continue reading -> New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Board Debates Medicines Access; WHO Asserts Mandate On IP, Trade Issues 30/01/2019 Catherine Saez Shortages, faulty supply chains, unbearable prices, weak health systems - the issue of access to medicines is multifaceted and gave way to a long list of interventions yesterday at the World Health Organization. Challenged on its mandate to address intellectual property and trade issues, WHO Director General Tedros Adhanom Gheyebresus (Dr Tedros) confirmed that WHO’s mandate includes work with partners on those issues. Discussions also included fair pricing and transparency, for which Italy called for a resolution at the next World Health Assembly. Continue reading -> Breaking News: WHO Board Completes Work On Access To Medicines Roadmap 29/01/2019 Catherine Saez After 65 interventions by member states and non-governmental organisations, at press time the World Health Organization Executive Board concluded work on a document containing a draft roadmap to increase access to medicines and vaccines. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New High-Tech System Against Falsified Medicines Goes Live In Europe 08/02/2019 William New A ground-breaking new high-tech patient safety system to catch falsified medicines in the supply chain in Europe went into effect today, allowing prescription medicines to undergo verification for authenticity before reaching patients. Continue reading -> High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Board Debates Medicines Access; WHO Asserts Mandate On IP, Trade Issues 30/01/2019 Catherine Saez Shortages, faulty supply chains, unbearable prices, weak health systems - the issue of access to medicines is multifaceted and gave way to a long list of interventions yesterday at the World Health Organization. Challenged on its mandate to address intellectual property and trade issues, WHO Director General Tedros Adhanom Gheyebresus (Dr Tedros) confirmed that WHO’s mandate includes work with partners on those issues. Discussions also included fair pricing and transparency, for which Italy called for a resolution at the next World Health Assembly. Continue reading -> Breaking News: WHO Board Completes Work On Access To Medicines Roadmap 29/01/2019 Catherine Saez After 65 interventions by member states and non-governmental organisations, at press time the World Health Organization Executive Board concluded work on a document containing a draft roadmap to increase access to medicines and vaccines. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
High Drug Prices Open Switzerland Up To Regional Procurement Ideas 07/02/2019 William New Switzerland, considered to be one of the richest countries in the world and home to significant medical research and development, has begun feeling the pressure of high drug prices for its citizens. This has led it to begin talking with other countries exploring joint procurement initiatives aimed at lowering prices, the Swiss global health ambassador told Health Policy Watch in a recent interview. Continue reading -> The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Board Debates Medicines Access; WHO Asserts Mandate On IP, Trade Issues 30/01/2019 Catherine Saez Shortages, faulty supply chains, unbearable prices, weak health systems - the issue of access to medicines is multifaceted and gave way to a long list of interventions yesterday at the World Health Organization. Challenged on its mandate to address intellectual property and trade issues, WHO Director General Tedros Adhanom Gheyebresus (Dr Tedros) confirmed that WHO’s mandate includes work with partners on those issues. Discussions also included fair pricing and transparency, for which Italy called for a resolution at the next World Health Assembly. Continue reading -> Breaking News: WHO Board Completes Work On Access To Medicines Roadmap 29/01/2019 Catherine Saez After 65 interventions by member states and non-governmental organisations, at press time the World Health Organization Executive Board concluded work on a document containing a draft roadmap to increase access to medicines and vaccines. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
The ‘Year Of UHC’ – Interview With Swiss Global Health Amb. Nora Kronig Romero 07/02/2019 Health Policy Watch Universal health coverage, access to medicines, and noncommunicable diseases are priorities for Switzerland in global health policy. Amb. Nora Kronig Romero is the head of the International Affairs Division and Vice Director General of the Federal Office of Public Health, as well as Swiss Ambassador for Global Health. She sat down with Health Policy Watch while in Geneva last week for the meeting of the World Health Organization Executive Board, which Switzerland attended as an observer to the governing board comprised of 34 WHO member states. Continue reading -> Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Board Debates Medicines Access; WHO Asserts Mandate On IP, Trade Issues 30/01/2019 Catherine Saez Shortages, faulty supply chains, unbearable prices, weak health systems - the issue of access to medicines is multifaceted and gave way to a long list of interventions yesterday at the World Health Organization. Challenged on its mandate to address intellectual property and trade issues, WHO Director General Tedros Adhanom Gheyebresus (Dr Tedros) confirmed that WHO’s mandate includes work with partners on those issues. Discussions also included fair pricing and transparency, for which Italy called for a resolution at the next World Health Assembly. Continue reading -> Breaking News: WHO Board Completes Work On Access To Medicines Roadmap 29/01/2019 Catherine Saez After 65 interventions by member states and non-governmental organisations, at press time the World Health Organization Executive Board concluded work on a document containing a draft roadmap to increase access to medicines and vaccines. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Civil Society Request Fair Pricing For Medicines, Transparency, At WHO 06/02/2019 Catherine Saez The fair pricing of medicines and the transparency of costs were underlined as key by many nongovernmental organisations last week during a discussion at the World Health Organization Executive Board on access to medicines. The Board heard about staggering numbers of people deprived of access to medication and health products, with examples from patients with epilepsy, kidney diseases and other illnesses preventing them from getting better or surviving their condition. Continue reading -> Board Debates Medicines Access; WHO Asserts Mandate On IP, Trade Issues 30/01/2019 Catherine Saez Shortages, faulty supply chains, unbearable prices, weak health systems - the issue of access to medicines is multifaceted and gave way to a long list of interventions yesterday at the World Health Organization. Challenged on its mandate to address intellectual property and trade issues, WHO Director General Tedros Adhanom Gheyebresus (Dr Tedros) confirmed that WHO’s mandate includes work with partners on those issues. Discussions also included fair pricing and transparency, for which Italy called for a resolution at the next World Health Assembly. Continue reading -> Breaking News: WHO Board Completes Work On Access To Medicines Roadmap 29/01/2019 Catherine Saez After 65 interventions by member states and non-governmental organisations, at press time the World Health Organization Executive Board concluded work on a document containing a draft roadmap to increase access to medicines and vaccines. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Board Debates Medicines Access; WHO Asserts Mandate On IP, Trade Issues 30/01/2019 Catherine Saez Shortages, faulty supply chains, unbearable prices, weak health systems - the issue of access to medicines is multifaceted and gave way to a long list of interventions yesterday at the World Health Organization. Challenged on its mandate to address intellectual property and trade issues, WHO Director General Tedros Adhanom Gheyebresus (Dr Tedros) confirmed that WHO’s mandate includes work with partners on those issues. Discussions also included fair pricing and transparency, for which Italy called for a resolution at the next World Health Assembly. Continue reading -> Breaking News: WHO Board Completes Work On Access To Medicines Roadmap 29/01/2019 Catherine Saez After 65 interventions by member states and non-governmental organisations, at press time the World Health Organization Executive Board concluded work on a document containing a draft roadmap to increase access to medicines and vaccines. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Breaking News: WHO Board Completes Work On Access To Medicines Roadmap 29/01/2019 Catherine Saez After 65 interventions by member states and non-governmental organisations, at press time the World Health Organization Executive Board concluded work on a document containing a draft roadmap to increase access to medicines and vaccines. Continue reading -> Posts navigation Older postsNewer posts